TCT26: Medtronic Symplicity blood pressure procedure shows significant blood pressure ...

Medtronic's SPYRAL AFFIRM study demonstrates significant and clinically meaningful blood pressure reductions at six months with the Symplicity Spyral renal denervation system without increasing antihypertensive medications. The FDA has approved a labeling update expanding the clinical data for use in patients with isolated systolic hypertension, chronic kidney disease stage up to 3b, and type 2 diabetes, broadening its treatment options in the U.S.

This Wire brief sits within Fusion42's coverage of Medtech.